Alison K. Conlin, MD
Portland, OR 97213
Providence Cancer Institute Franz Clinic
4805 Northeast Glisan Street, Suite 11N-1, Portland, OR 97213
Are you covered?
Check to see if your insurance is covered by this provider.
About Alison K. Conlin
"We aim to care for our patients with the utmost respect and compassion while offering the most advanced treatments and options to participate in new and exciting clinical trials. Our focus is always on the patient and helping them and their family members feel the complete care they are receiving." - Alison Conlin, M.D.
Dr. Conlin's interests are in both early and advanced stage breast cancer and the development and incorporation of new drugs for these patients. She sees patients in Portland, OR.
Memorial Sloan-Kettering Cancer Center
2008
Weill Cornell Medical Center
Medical School
State University of New York Upstate Medical University
2002
Weill Cornell Medical Center
2005
- American Board of Internal Medicine, Medical Oncology
- Tucatinib Combined With Ado-Trastuzumab Emtansine in Advanced ERBB2/HER2-Positive Metastatic Breast Cancer: A Phase 1b Clinical Trial.
- Tucatinib with capecitabine and trastuzumab in advanced HER2-positive metastatic breast cancer with and without brain metastases: a non-randomised, open-label, phase 1b study.
- Cognitive Complaints in Survivors of Breast Cancer After Chemotherapy Compared With Age-Matched Controls: An Analysis From a Nationwide, Multicenter, Prospective Longitudinal Study.
- Epirubicin With Cyclophosphamide Followed by Docetaxel With Trastuzumab and Bevacizumab as Neoadjuvant Therapy for HER2-Positive Locally Advanced Breast Cancer or as Adjuvant Therapy for HER2-Positive Pathologic Stage III Breast Cancer: A Phase II Trial of the NSABP Foundation Research Group, FB-5.
- What does Medicaid expansion mean for cancer screening and prevention? Results from a randomized trial on the impacts of acquiring Medicaid coverage.
- Phase II trial of patupilone in patients with brain metastases from breast cancer.
- Randomized phase II trial of weekly vs. every 2 weeks vs. every 3 weeks nanoparticle albumin-bound paclitaxel with bevacizumab as first-line chemotherapy for metastatic breast cancer.
- Serum N-telopeptide and bone-specific alkaline phosphatase levels in patients with osteonecrosis of the jaw receiving bisphosphonates for bone metastases.
- Phase II trial of weekly nanoparticle albumin-bound paclitaxel with carboplatin and trastuzumab as first-line therapy for women with HER2-overexpressing metastatic breast cancer.
- Beyond cytotoxic chemotherapy for the first-line treatment of HER2-negative, hormone-insensitive metastatic breast cancer: current status and future opportunities.
- Use of the Oncotype DX 21-gene assay to guide adjuvant decision making in early-stage breast cancer.
- Point: combination versus single-agent chemotherapy: the argument for sequential single agents.
- Taxanes in breast cancer: an update.
- Dermatological toxicity of ixabepilone.
4805 Northeast Glisan Street, Suite 11N-1
Portland, OR 97213
Providence Medical Group - Oregon
Providence Portland Medical Center
Providence St. Vincent Medical Center
Providence Milwaukie Hospital
Providence Newberg Medical Center
Providence Willamette Falls Medical Center
Providence Seaside Hospital
Providence Hood River Memorial Hospital